Phase 2 Study of Nivolumab vs Nivolumab Plus Ipilimumab for GIST

Share this content:
Researchers are comparing the efficacy of nivolumab monotherapy with that of nivolumab plus ipilimumab in patients with an unresectable or metastatic GIST.
Researchers are comparing the efficacy of nivolumab monotherapy with that of nivolumab plus ipilimumab in patients with an unresectable or metastatic GIST.

Title: A Randomized Phase 2 Study of Nivolumab Monotherapy Versus Nivolumab Combined With Ipilimumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)1

Principal Investigator: Arun Singh, MD, Jonsson Comprehensive Cancer Center

Description: For this open-label phase 2 study (ClinicalTrials.gov Identifier: NCT02880020), researchers are comparing the efficacy of nivolumab monotherapy with that of nivolumab plus ipilimumab in patients with an unresectable or metastatic GIST.

Patients will receive intravenous (IV) nivolumab on day 1 of 2 week cycles for up to 2 years or IV nivolumab on day 1 of 2 week cycles plus IV ipilimumab every 6 weeks for up to 2 years.

The primary outcome measure is the overall response rate. Secondary outcomes include the clinical benefit rate, toxicity, progression-free survival, and response rate by Choi criteria. 

The estimated study enrollment is 40 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02880020.

Status: Open and recruiting patients as of November 22, 2017.

This study is sponsored by the Jonsson Comprehensive Cancer Center in collaboration with the National Cancer Institute.

Reference

  1. ClinicalTrials.gov. Nivolumab with or without ipilimumab in treating patients with gastrointestinal stromal tumor that is metastatic or cannot be removed by surgery. NCT02880020. https://clinicaltrials.gov/ct2/show/NCT02880020. Accessed November 22, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters